(Total Views: 74)
Posted On: 05/05/2017 2:23:43 PM
Post# of 2218
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
$ EXEL Growth Stock oncology pick Exelixis (NASDAQ: EXEL) which has quadrupled in the last year on back of a beautifully managed roll-out of its drug Cabometyx. Those stories are far and few between like most budding romances.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)